Cong Lin

Amsterdam, NH 1105AZ, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

CCAAT/enhancer binding protein delta (C/EBPδ) deficiency does not affect bleomycin-induced pulmonary fibrosis.

CCAAT/enhancer binding protein delta (C/EBPδ) deficiency does not affect bleomycin-induced pulmonary fibrosis.

Journal: Journal of clinical and translational research
Published: March 16, 2019

The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease.

The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease.

Journal: Experimental biology and medicine (Maywood, N.J.)
Published: September 29, 2018

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer.

Journal: BMC cancer
Published: August 03, 2016

High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis.

High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis.

Journal: Journal of cellular and molecular medicine
Published: February 23, 2016

Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels.

Increased Mortality during Bleomycin-induced Pulmonary Fibrosis due to Low Endogenous Activated Protein C Levels.

Journal: American journal of respiratory and critical care medicine
Published: November 17, 2015

Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis.

Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis.

Journal: Oncotarget
Published: August 12, 2015

Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis.

Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis.

Journal: Molecular medicine (Cambridge, Mass.)
Published: April 23, 2015

Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis.

Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis.

Journal: Journal of cellular and molecular medicine
Published: June 27, 2014

Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis.

Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis.

Journal: Thorax
Published: September 14, 2013
Showing 1-9 of 9

Last Updated: 09/26/2026